Conclusion Research involving GLP-1 receptor agonists and Parkinsons disease continues to expand as scientists investigate how metabolic therapies may influence neurodegeneration
While more research is needed, the picture is promising
Written by Ali Rza Akn Microbiome Scientist, Author & Founder of Next-Microbiome Ali Rza Akn is a microbiome scientist with nearly 30 years of experience in translational biotechnology, systems biology, and applied microbiome research, spanning discovery, preclinical development, and clinical-stage translation
A double-blind trial of a glucomannan, inulin, and psyllium blend reported a 4.9 percent treatment difference over 180 days, but with a 74.6 percent rate of (mostly mild and transient) gastrointestinal adverse events versus none on placebo, which underlines that GI tolerability, driven by viscosity and fermentation, is the central fiber formulation challenge [5]
Ozempic (semaglutide) is a prescription medication that is approved only in injectable form
Adding GHRP-6 or Hexarelin on top of this combination does not produce additive GH release